| Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies JJ Castillo, N Mull, JL Reagan, S Nemr, J Mitri Blood, The Journal of the American Society of Hematology 119 (21), 4845-4850, 2012 | 230 | 2012 |
| Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either … G Ratzinger, J Baggers, A Maria, J Yuan, T Dao, JL Reagan, C Münz, ... The Journal of Immunology 174 (6), 3818-3818, 2005 | 214 | 2005 |
| Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either … G Ratzinger, J Baggers, A Maria, J Yuan, T Dao, JL Reagan, C Münz, ... The Journal of Immunology 173 (4), 2780-2791, 2004 | 214 | 2004 |
| Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83 B Sénéchal, AM Boruchov, JL Reagan, DNJ Hart, JW Young Blood 103 (11), 4207-4215, 2004 | 207 | 2004 |
| Plasmablastic lymphoma: a systematic review JJ Castillo, JL Reagan The Scientific World Journal 11, 687-696, 2011 | 169 | 2011 |
| Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host … G Ratzinger, JL Reagan, G Heller, KJ Busam, JW Young Blood, The Journal of the American Society of Hematology 101 (4), 1422-1429, 2003 | 164 | 2003 |
| Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies JJ Castillo, JL Reagan, RR Ingham, M Furman, S Dalia, B Merhi, S Nemr, ... Leukemia research 36 (7), 868-875, 2012 | 133 | 2012 |
| Bortezomib in combination with infusional dose‐adjusted EPOCH for the treatment of plasmablastic lymphoma JJ Castillo, JL Reagan, WM Sikov, ES Winer British Journal of Haematology 169 (3), 352-355, 2015 | 93 | 2015 |
| Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma JJ Castillo, T Guerrero-Garcia, F Baldini, E Tchernonog, G Cartron, ... British Journal of Haematology 184 (4), 679-682, 2019 | 76 | 2019 |
| Extracellular vesicles in leukemia A Pando, JL Reagan, P Quesenberry, LD Fast Leukemia research 64, 52-60, 2018 | 62 | 2018 |
| Obesity is associated with increased relative risk of diffuse large B-cell lymphoma: a meta-analysis of observational studies JJ Castillo, RR Ingham, JL Reagan, M Furman, S Dalia, J Mitri Clinical Lymphoma Myeloma and Leukemia 14 (2), 122-130, 2014 | 53 | 2014 |
| Potential biomarkers to detect traumatic brain injury by the profiling of salivary extracellular vesicles Y Cheng, M Pereira, N Raukar, JL Reagan, M Queseneberry, L Goldberg, ... Journal of cellular physiology 234 (8), 14377-14388, 2019 | 51 | 2019 |
| Multiple myeloma-induced hyperammonemic encephalopathy: An entity associated with high in-patient mortality A Pham, JL Reagan, JJ Castillo Leukemia research 37 (10), 1229-1232, 2013 | 47 | 2013 |
| Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK‐ERK and NF‐κB pathways in a model of chronic myeloid leukemia A Chorzalska, N Ahsan, RSP Rao, K Roder, X Yu, J Morgan, A Tepper, ... Molecular oncology 12 (5), 630-647, 2018 | 41 | 2018 |
| IgM myeloma: a multicenter retrospective study of 134 patients JJ Castillo, A Jurczyszyn, L Brozova, E Crusoe, J Czepiel, J Davila, ... American journal of hematology 92 (8), 746-751, 2017 | 41 | 2017 |
| The return of gemtuzumab ozogamicin: A humanized anti-CD33 monoclonal antibody–drug conjugate for the treatment of newly diagnosed acute myeloid leukemia PC Egan, JL Reagan OncoTargets and therapy 11, 8265, 2018 | 35 | 2018 |
| Cellular immunotherapy for refractory hematological malignancies JL Reagan, LD Fast, H Safran, M Nevola, ES Winer, JJ Castillo, JN Butera, ... Journal of translational medicine 11 (1), 150, 2013 | 34 | 2013 |
| Marrow cell genetic phenotype change induced by human lung cancer cells M Del Tatto, T Ng, JM Aliotta, GA Colvin, MS Dooner, D Berz, GJ Dooner, ... Experimental hematology 39 (11), 1072-1080, 2011 | 33 | 2011 |
| Time to treatment is an independent prognostic factor in aggressive non‐Hodgkin lymphomas AJ Olszewski, T Ollila, JL Reagan British journal of haematology 181 (4), 495-504, 2018 | 29 | 2018 |
| Mechanisms of hypercalcemia in non-Hodgkin lymphoma and associated outcomes: a retrospective review RM Shallis, RS Rome, JL Reagan Clinical Lymphoma Myeloma and Leukemia 18 (2), e123-e129, 2018 | 28 | 2018 |
